MX2023013436A - Terapias de combinacion. - Google Patents

Terapias de combinacion.

Info

Publication number
MX2023013436A
MX2023013436A MX2023013436A MX2023013436A MX2023013436A MX 2023013436 A MX2023013436 A MX 2023013436A MX 2023013436 A MX2023013436 A MX 2023013436A MX 2023013436 A MX2023013436 A MX 2023013436A MX 2023013436 A MX2023013436 A MX 2023013436A
Authority
MX
Mexico
Prior art keywords
sup
inhibitor
agent
combinations
effective amount
Prior art date
Application number
MX2023013436A
Other languages
English (en)
Inventor
Olivier Alexis Georges Querolle
Wei Cai
Ming Li
Vineet Pande
Ulrike Philippar
Xuedong Dai
Liqiang Fu
Yingtao Liu
Yanping Xu
Kathryn Elizabeth Packman
Xiangjun Deng
Lianzhu Liu
Lichao Fang
Alicia Tee Fuay Ng
DARVILLE Nicolas Freddy J
Johannes Wilhelmus J Thuring
Nikki Daskalakis
Christina Diane Guttke
Min Chul Kwon
Lucille Angela Ferrante
Eva Christine Pietsch
VERHULST Tinne Ann J
Sumia Ali-Ahmed
Balpreet Bhogal
Yu Sun
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2023013436A publication Critical patent/MX2023013436A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen combinaciones que comprenden una cantidad terapéuticamente efectiva de un inhibidor de menina-MLL de la Fórmula (I) o una sal o un solvato farmacéuticamente aceptable de este; y una cantidad terapéuticamente efectiva de al menos un otro agente terapéutico que es un agente hipometilante, un inhibidor de citidina desaminasa, un agente intercalante del ADN, un análogo de pirimidina, un análogo de purina, un inhibidor de cinasa, un inhibidor de CD20, un inhibidor de IDH, un agente inmunomodulador o un inhibidor de DHODH. También se describen métodos para tratar a un sujeto que ha sido diagnosticado con cáncer usando tales combinaciones. Los compuestos se representan por la Fórmula (I) como sigue: en donde R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 y n4 se definen en la presente descripción.
MX2023013436A 2021-05-11 2022-05-09 Terapias de combinacion. MX2023013436A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2021093036 2021-05-11
CN2021100522 2021-06-17
CN2021100523 2021-06-17
CN2022086004 2022-04-11
CN2022086003 2022-04-11
PCT/CN2022/091678 WO2022237719A1 (en) 2021-05-11 2022-05-09 Combination therapies

Publications (1)

Publication Number Publication Date
MX2023013436A true MX2023013436A (es) 2023-12-12

Family

ID=81753153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013436A MX2023013436A (es) 2021-05-11 2022-05-09 Terapias de combinacion.

Country Status (14)

Country Link
EP (1) EP4337215A1 (es)
JP (1) JP2024519322A (es)
KR (1) KR20240006638A (es)
CN (1) CN117337180A (es)
AU (1) AU2022271993A1 (es)
CA (1) CA3214861A1 (es)
CO (1) CO2023014325A2 (es)
DO (1) DOP2023000239A (es)
IL (1) IL308333A (es)
MX (1) MX2023013436A (es)
PE (1) PE20240588A1 (es)
TW (1) TW202308642A (es)
UY (1) UY39762A (es)
WO (1) WO2022237719A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
WO2024114664A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3233857T3 (pl) 2014-12-18 2020-07-27 Takeda Pharmaceutical Company Limited Stałe postacie skondensowanych heteroaromatycznych pirolidynonów
PL3468966T3 (pl) * 2016-06-10 2021-04-06 Vitae Pharmaceuticals, Llc Inhibitory interakcji menina-mll
JP2020514388A (ja) * 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
WO2021121327A1 (en) 2019-12-19 2021-06-24 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Also Published As

Publication number Publication date
CN117337180A (zh) 2024-01-02
WO2022237719A1 (en) 2022-11-17
PE20240588A1 (es) 2024-03-21
DOP2023000239A (es) 2024-04-30
CO2023014325A2 (es) 2023-10-30
UY39762A (es) 2022-11-30
EP4337215A1 (en) 2024-03-20
JP2024519322A (ja) 2024-05-10
AU2022271993A1 (en) 2024-01-04
KR20240006638A (ko) 2024-01-15
TW202308642A (zh) 2023-03-01
IL308333A (en) 2024-01-01
CA3214861A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
MX2023013436A (es) Terapias de combinacion.
MX2020013570A (es) Compuestos de purinona y su uso en el tratamiento del cancer.
CR20220258A (es) Inhibidores de kras g12c
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
CR20210670A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
MX2023009185A (es) Compuestos de benzamida.
MY147628A (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
MX2022007372A (es) Compuestos de heteroarilo sustituidos utiles como activadores de celulas t.
CR20210409A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
MX2022006958A (es) Compuestos de quinazolinilo sustituidos utiles como activadores de celulas t.
MX2021007829A (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso para tratar el cancer.
CR20220675A (es) Análogos de nucleósido de 1´- ciano y usos de los mismos
MX2007003603A (es) Metodos para preparar compuestos de indazol.
WO2004074270A3 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
MA31679B1 (fr) Cuclopentanes de pyrimidyle comme inhibiteurs de proteines kinases akt
WO2007067364A3 (en) Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs
MX2022007842A (es) Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2018013325A (es) Derivados de adenina como inhibidores de proteína quinasa.
MX2022002219A (es) Triazolopirimidinas como inhibidores de a2a/a2b.
MX2023013410A (es) Terapias de combinacion.
Han et al. Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors
ZA202208541B (en) Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof